216 related articles for article (PubMed ID: 24955100)
1. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Evid Based Complement Alternat Med; 2014; 2014():236310. PubMed ID: 24955100
[TBL] [Abstract][Full Text] [Related]
2. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
3. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Evid Based Complement Alternat Med; 2014; 2014():724258. PubMed ID: 24672577
[TBL] [Abstract][Full Text] [Related]
4. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
[TBL] [Abstract][Full Text] [Related]
8. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador.
Urech K; Schaller G; Jäggy C
Arzneimittelforschung; 2006 Jun; 56(6A):428-34. PubMed ID: 16927522
[TBL] [Abstract][Full Text] [Related]
9. Safety of Combined Targeted and Helixor
Schad F; Thronicke A
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767928
[TBL] [Abstract][Full Text] [Related]
10. Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study.
Baek JH; Jeon Y; Han KW; Jung DH; Kim KO
World J Surg Oncol; 2021 Jun; 19(1):178. PubMed ID: 34130688
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
Büssing A
Arzneimittelforschung; 2006 Jun; 56(6A):508-15. PubMed ID: 16927532
[TBL] [Abstract][Full Text] [Related]
12. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
13. Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations.
Zuzak TJ; Rist L; Eggenschwiler J; Grotzer MA; Viviani A
Anticancer Res; 2006; 26(5A):3485-92. PubMed ID: 17094471
[TBL] [Abstract][Full Text] [Related]
14. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
Schad F; Axtner J; Kröz M; Matthes H; Steele ML
Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
[TBL] [Abstract][Full Text] [Related]
15. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
Bar-Sela G; Gershony A; Haim N
Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
[TBL] [Abstract][Full Text] [Related]
16. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
Grossarth-Maticek R; Ziegler R
Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
[TBL] [Abstract][Full Text] [Related]
17. Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects.
Lederer AK; Rieger S; Schink M; Huber R
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543063
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
Melzer J; Iten F; Hostanska K; Saller R
Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
[TBL] [Abstract][Full Text] [Related]
19. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
20. Radioprotective effects of mistletoe extract in zebrafish embryos in vivo.
Rim CH; Koun S; Park HC; Lee S; Kim CY
Int J Radiat Biol; 2019 Aug; 95(8):1150-1159. PubMed ID: 30836032
[No Abstract] [Full Text] [Related]
[Next] [New Search]
